In February, the country’s medicines regulator - the Therapeutic Goods Administration - agreed to change the classification for certain products containing small amounts of cannabidiol , an active ingredient in the cannabis plant that does not get the user high but is used in therapeutic products.
Cann Group is optimistic it can be one of the first producers to bring a “schedule 3” drug to market.“The interest in medicinal cannabis is strong, and it continues to grow,” said chief executive of ASX-listed cannabis company Cann Group, Peter Crock.
The TGA says there is scientific evidence to support the use of CBD capsules to treat chronic pain, anxiety and sleep issues, but any over-the-counter medicines will have to provide robust evidence that they work for one particular ailment.Loading Chief executive Dr Michael Winlo said in a research presentation last month the company hopes to have its product registered for use by the end of next year.Australia’s medicinal cannabis sector isand the decision to allow some products to be sold at the pharmacy level will help companies capture more consumers. In the US, consumers are set to spend $US23 billion a year on legal cannabis by 2025, according to projections from business insights firm Statista.
MsEmmaK Pointless if it’s low dose, that’s why I’m leaving Australia and it’s backwards people
MsEmmaK It will happen as soon as the rich fucks cornering all the stock options on the companies allowed to do this through under the table deals with politicians get their shell companies set up offshore to handle all their profits.